Clinical Trial Update: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. [Phase 2]

View source ↗

Summary

This update presents efficacy and safety results from a Phase 2 trial of ribociclib in pre- and postmenopausal Chinese women with HR-positive, HER2-negative adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED